| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Hsu F.-M;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Chih-Hsin Yang; Lee J.-H; Chen H.-Y; Hsu F.-M; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y;Liao W.-Y;Ho C.-C;Chen K.-Y;Tsai T.-H;Hsu C.-L;Su K.-Y;Chang Y.-L;Wu C.-T;Hsu C.-C;Liao B.-C;Hsu W.-H;Lee J.-H;Lin C.-C;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chia-Chi Lin; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T02:45:22Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Feng-Ming Hsu;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Yang J.C.-H.; Lee J.-H; Chen H.-Y; Feng-Ming Hsu; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T01:32:56Z |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
Shih J.-Y.;Yu C.-J.;Liu Y.-N.;Wu S.-G.;Tsai T.-H.;YEN-TING LIN; YEN-TING LIN; Tsai T.-H.; Wu S.-G.; Liu Y.-N.; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:41Z |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
Shih J.-Y.; Yu C.-J.; Liu Y.-N.; Wu S.-G.; Tsai T.-H.; YEN-TING LIN; Shih J.-Y.;Yu C.-J.;Liu Y.-N.;Wu S.-G.;Tsai T.-H.;YEN-TING LIN |
| 臺大學術典藏 |
2020-04-28T07:13:21Z |
Advancing a smart air cushion system for preventing pressure ulcers using projection Moir? for large deformation measurements
|
Cheng, S.-L.; Tsai, T.-H.; Lee, C.J.-T.; Hsu, Y.-H.; Lee, C.-K.; YU-HSIANG HSU |
| 臺大學術典藏 |
2020-04-28T07:12:06Z |
A novel acoustofluidic device for antigen antibody interaction detection using electrochemical impedance measurement
|
Tsai, T.-H.;Lee, C.-K.; Tsai, T.-H.; Lee, C.-K.; CHIH-KUNG LEE |
| 臺大學術典藏 |
2020-04-28T07:12:03Z |
Advancing a smart air cushion system for preventing pressure ulcers using projection Moir? for large deformation measurements
|
CHIH-KUNG LEE; Lee, C.-K.; Hsu, Y.-H.; Lee, C.J.-T.; Tsai, T.-H.; Cheng, S.-L.; Cheng, S.-L.;Tsai, T.-H.;Lee, C.J.-T.;Hsu, Y.-H.;Lee, C.-K. |
| 臺大學術典藏 |
2020-04-16T02:35:26Z |
A Takagi-Sugeno fuzzy neural network-based algorithm with single-channel EEG signal for the discrimination between light and deep sleep stages
|
Tsai, T.-H.; Kau, L.-J.; Chao, K.-M.; KUN-MA0 CHAO |
| 臺大學術典藏 |
2020-04-16T02:35:07Z |
U-care for the elderly: Implemenation of a comprehensive living and health care network
|
Chen, H.-S.; Su, M.-J.; Tsai, T.-H.; Teng, S.-S.; Zhang, H.-W.; Jin-Shin, L.; Lai, F.-P.; Chen, C.-Y.; FEI-PEI LAI |
| 臺大學術典藏 |
2020-03-31T08:54:40Z |
Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis
|
Yang P.-C.; LI-NA LEE; Hsueh P.-R.; Yu C.-J.; Hsu C.-L.; Tsai T.-H.; Wang J.-T.; Wang J.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:42Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Jin-Shing Chen;Liao W.-Y.;Shih J.-Y.;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; JIN-SHING CHEN; Liao W.-Y.; Shih J.-Y.; Yu C.-J.; Chen K.-Y.; Tsai T.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-27T05:30:07Z |
Hypoglycemia associated with bacteremic pneumococcal infections
|
Lee L.-N.;PO-REN HSUEH;Hung P.-L.;Hsu H.-F.;Jerng J.-S.;Chen J.-M.;Tsai T.-H.;Jan I.-S.; Jan I.-S.; Tsai T.-H.; Chen J.-M.; Jerng J.-S.; Hsu H.-F.; Hung P.-L.; PO-REN HSUEH; Lee L.-N. |
| 臺大學術典藏 |
2020-03-27T05:30:03Z |
Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis
|
Yang P.-C.; Lee L.-N.; PO-REN HSUEH; Yu C.-J.; Hsu C.-L.; Wang J.-T.; Tsai T.-H.; Wang J.-Y.; Yang P.-C.;Lee L.-N.;PO-REN HSUEH;Yu C.-J.;Hsu C.-L.;Tsai T.-H.;Wang J.-T.;Wang J.-Y. |
| 臺大學術典藏 |
2020-03-07T06:56:35Z |
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
|
Tsai T.-H.; Wu S.-G.; YIH-LEONG CHANG; Wu C.-T.; Tsai M.-F.; Wei P.-F.; Yang C.-H.; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-07T06:56:34Z |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
|
Tsai T.-H.; Su K.-Y.; Wu S.-G.; YIH-LEONG CHANG; Luo S.-C.; Jane I.-S.; Yu C.-J.; Yue S.-L.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-07T06:56:27Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.;Hsieh M.-S.;Wu S.-G.;Yih-Leong Chang;Shih J.-Y.;Liu Y.-N.;Tsai M.-F.;Tsai T.-H.;Yu C.-J.;Yang J.C.-H.;Yang P.-C.; YIH-LEONG CHANG; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Chen Y.-F.; Hsieh M.-S.; Wu S.-G. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Yih-Leong Chang;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Yih-Leong Chang;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-07T06:56:10Z |
Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
|
Liu Y.-N.;Tsai M.-F.;Wu S.-G.;Chang T.-H.;Tsai T.-H.;Gow C.-H.;Yih-Leong Chang;Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; Tsai T.-H.; Gow C.-H.; YIH-LEONG CHANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-07T06:56:09Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Yih-Leong Chang;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:22Z |
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
|
Tsai T.-H.; Wu S.-G.; YIH-LEONG CHANG; Wu C.-T.; Tsai M.-F.; Wei P.-F.; Yang C.-H.; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:21Z |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
|
Tsai T.-H.; Su K.-Y.; Wu S.-G.; YIH-LEONG CHANG; Luo S.-C.; Jane I.-S.; Yu C.-J.; Yue S.-L.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:17Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; YIH-LEONG CHANG; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:01Z |
Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
|
Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; Tsai T.-H.; Gow C.-H.; YIH-LEONG CHANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:00Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-05T08:16:38Z |
Histopathological and genetic analysis of extraocular muscle in chronic progressive external ophthalmoplegia
|
Hsiao C.-C.; Lee N.-C.; PEI-HSIN HUANG; Tsai T.-H. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-05T08:04:09Z |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.; Wu S.-G.; MIN-SHU HSIEH; Yu C.-J.; Yang J.C.H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-03T03:46:00Z |
Aggrenox (Asasantin retard)-induced Stevens-Johnson syndrome
|
Jao T.; Tsai T.-H.; JIANN-SHING JENG |
| 臺大學術典藏 |
2020-03-03T03:06:22Z |
White matter microstructural alterations in amblyopic adults revealed by diffusion spectrum imaging with systematic tract-based automatic analysis
|
Tsai T.-H.;Su H.-T.;Hsu Y.-C.;Shih Y.-C.;Chen C.-C.;Hu F.-R.;Wen-Yih Tseng; Tsai T.-H.; Su H.-T.; Hsu Y.-C.; Shih Y.-C.; Chen C.-C.; Hu F.-R.; WEN-YIH TSENG |
| 臺大學術典藏 |
2020-02-26T01:36:55Z |
Visualizing radiofrequency-skin interaction using multiphoton microscopy in vivo
|
Tsai, T.-H.; Lin, S.-J.; Lee, W.-R.; Wang, C.-C.; Hsu, C.-T.; Chu, T.; Dong, C.-Y.; SUNG-JAN LIN |
| 臺大學術典藏 |
2020-02-20T02:57:03Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y.; Ruan S.-Y.; Wang J.-Y.; Chen K.-Y.; Jan I.-S.; Tsai T.-H.; CHING-YAO YANG; Ho C.-C.; Liao W.-Y. |
| 臺大學術典藏 |
2020-02-07T03:43:34Z |
Better Osteoporotic Fracture Healing with Sintered Dicalcium Pyrophosphate (SDCP) Treatment: A Rat Femoral Fracture Model
|
Kuo Y.-J.;Jui-Sheng Sun;Rau G.;Chen C.-H.;Tsai T.-H.;Tsuang Y.-H.; Kuo Y.-J.; JUI-SHENG SUN; Rau G.; Chen C.-H.; Tsai T.-H.; Tsuang Y.-H. |
| 臺大學術典藏 |
2020-01-13T08:24:59Z |
Wide-bandwidth piezoelectric energy harvester integrated with parylene-C beam structures
|
Yang, Y.-J.; YAO-JOE YANG; Tsai, T.-H.; Huang, P.-C. |
| 臺大學術典藏 |
2020-01-13T08:23:09Z |
Fast mixing of the ferrofluid in microchannels
|
Chang, C.W.; Tsai, T.H.; Chiang, T.C.; Wang, P.Y.; Hsieh, Y.F.; Chang, C.H.; Chen, P.H.; PING-HEI CHEN |
| 臺大學術典藏 |
2020-01-13T08:23:08Z |
Enhancement of mixing performance of water solutions in a micro-mixer with immiscible ferrofluid
|
Tsai, T.-H.; Liou, D.-S.; Chen, P.-H.; Yang, C.-T.; PING-HEI CHEN |
| 臺大學術典藏 |
2020-01-13T08:23:08Z |
Applications of nanofluids in microfluidic devices
|
Chen, P.-H.; Liou, D.-S.; Tsai, T.-H.; Kuo, L.-S.; Yang, C.-T.; PING-HEI CHEN |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yu C.-J.; Yang J.C.-H.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
